Physician profile

Maxine Barrett

Adult Health (Nurse Practitioner) · New York, NY

NPI 1588875108

$3,043.23

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,387.35

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $1,041.78 2021-2024 Xarelto
Pfizer INC. $622.81 2021-2024
Astrazeneca Pharmaceuticals LP $433.34 2022-2024 Farxiga
Boehringer Ingelheim Pharmaceuticals, INC. $419.62 2022-2024 Jardiance
Novartis Pharmaceuticals Corporation $235.57 2021-2024
E.R. Squibb & Sons, L.L.C. $175.61 2022-2023 Camzyos
Abbvie INC. $88.41 2023-2024
Gilead Sciences, INC. $26.09 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maxine Barrett

$3,043.23

in general payments reported 2019-2025

Years
2021-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/10538821/maxine-barrett

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.